Non-invasive fetal RhD screening

Targeted medicine

Detect rhesus disease risk

By detecting the blood rhesus status of a fetus during pregnancy, genetic screening can determine the risk of rhesus or hemolytic disease – a condition where antibodies in the rhesus-negative blood of a pregnant woman attack her rhesus-positive fetus’s blood cells.

Avoid unnecessary treatment

Non-invasive detection of fetal RHD status allows clinicians to target antenatal prophylaxis only at RHD-negative women carrying a D-positive fetus, thereby eliminating the unnecessary administration of human blood-based products and reducing immunization.

Screen prenatally

Highly sensitive and accurate diagnostic tests with low DNA input today allow fetal RHD testing to shift from the research environment to clinical labs as part of large prenatal screening programs.

Proven results

Our non-invasive genetic screening technology accurately detects fetal rhesus status in pregnant women with high sensitivity and accuracy.

Devyser’s fetal RHD testing solution has been proven in clinical laboratory environments for more than a decade. They meet the high – and growing – demands on testing procedures as laboratories seek robust, standardized workflows adapted to high-throughput screening.

Devyser RHD is a next-generation test solution that uses a single-exon assay to deliver a simple workflow leading to fast and reliable results .

The CE-IVD test kit determines fetal RHD status from maternal plasma as early as the tenth week of pregnancy. The kit is highly sensitive and requires low DNA input.

Devyser RHD optimizes the entire lab workflow – including sample handling, data interpretation, and results reporting. The result: more productive laboratories with higher throughput where accurate results are assured.